MET Mutations in Non-Small Cell Lung Cancer: A Case Series
-
- STATUS
- None
Summary
Mutations in the MET proto-oncogene account for a small, but targetable, subset of non-small cell lung cancers. While a small, prospective study of 4 patients treated with the MET inhibitors crizotinib or cabozantinib reports response in patients with MET exon 14 skipping mutations, this is the biggest study in this patient population. We intend to add to this sparse body of literature by retrospectively reporting our experience with using MET inhibitors in patients with MET mutated non-small cell lung cancer.
Details
| Condition | TBD, tbd, tbd |
|---|---|
| Age | 99years or below |
| Clinical Study Identifier | TBD |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.